Pemphigus Vulgaris Clinical Trial
Official title:
A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active PV requiring 60-120 milligrams per day (mg/day) oral prednisone or equivalent. Participants must have a confirmed diagnosis of PV within the previous 24 months (by skin or mucosal biopsy and immunohistochemistry) and evidence of active disease at screening. Approximately 135 participants will be enrolled at up to 60 centers worldwide. Participants will be randomized in a 1:1 ratio to receive either rituximab plus MMF placebo or rituximab placebo plus MMF. Randomization will be stratified by duration of illness. The study will consist of three periods: a screening period of up to 28 days, a 52-week double-blind treatment period, and a 48-week safety follow up period that begins at the time of study treatment completion or discontinuation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04422912 -
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
|
Phase 1 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT04117529 -
Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
|
N/A | |
| Completed |
NCT03334058 -
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
|
Phase 2 | |
| Terminated |
NCT03239470 -
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
|
Phase 1 | |
| Completed |
NCT00606749 -
Use of KC706 for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
| Terminated |
NCT00429533 -
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
|
Phase 2 | |
| Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
| Withdrawn |
NCT03780166 -
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
|
Phase 2 | |
| Recruiting |
NCT04096222 -
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
|
||
| Not yet recruiting |
NCT03177213 -
Serum IL-21 Levels in Patients With Pemphigus Vulgaris
|
N/A | |
| Completed |
NCT00135720 -
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
| Completed |
NCT00063752 -
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
|
Phase 1 | |
| Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04598477 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
|
Phase 3 | |
| Completed |
NCT02704429 -
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
|
Phase 2 | |
| Completed |
NCT00626678 -
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
|
Phase 2 | |
| Active, not recruiting |
NCT05338112 -
Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
|
||
| Completed |
NCT06167408 -
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
|
||
| Recruiting |
NCT05303272 -
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
|
Phase 4 |